The ENABLE Study: Safety and Efficacy Study of INZ-701 in Patients With ENPP1 Deficiency

Phase 2 Withdrawn Inozyme Pharma

NaSingle-groupOpen-labelTreatment

Summary

The purpose of Study INZ701-108 (ENABLE) is to assess the safety and efficacy of INZ-701 in patients 1 year of age and older with ENPP1 Deficiency who have not previously received INZ-701 and are not eligible for existing Inozyme-sponsored clinical studies that are still open to enrollment.

Timeline

Start: 2025-01-31
Primary completion: 2027-03-31
Completion: 2028-03-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	INZ-701	Protein / enzyme biologic	1.8 mg/kg	Subcutaneous
Subject	INZ-701	Protein / enzyme biologic	2.4 mg/kg	Subcutaneous
Subject	INZ-701	Protein / enzyme biologic	150 mg	Subcutaneous

The ENABLE Study: Safety and Efficacy Study of INZ-701 in Patients With ENPP1 Deficiency

Summary

Timeline

Drugs

Indications